Current status of liquid biopsies for the detection and management of prostate cancer
| Autor: | Amir Goldkorn, Yi-Tsung Lu, Andrew Mecum, Kevin Delijani |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
business.industry medicine.disease Microvesicles Management of prostate cancer Androgen receptor 03 medical and health sciences Prostate cancer Circulating MicroRNA 030104 developmental biology 0302 clinical medicine Circulating tumor cell Oncology 030220 oncology & carcinogenesis medicine Cancer research Biomarker (medicine) Liquid biopsy business |
| Zdroj: | Cancer Management and Research. 11:5271-5291 |
| ISSN: | 1179-1322 |
| DOI: | 10.2147/cmar.s170380 |
| Popis: | In recent years, new therapeutic options have become available for prostate cancer (PC) patients, generating an urgent need for better biomarkers to guide the choice of therapy and monitor treatment response. Liquid biopsies, including circulating tumor cells (CTCs), circulating nucleic acids, and exosomes, have been developed as minimally invasive assays allowing oncologists to monitor PC patients with real-time cellular or molecular information. While CTC counts remain the most extensively validated prognostic biomarker to monitor treatment response, recent advances demonstrate that CTC morphology and androgen receptor characterization can provide additional information to guide the choice of treatment. Characterization of cell-free DNA (cfDNA) is another rapidly emerging field with novel technologies capable of monitoring the evolution of treatment relevant alterations such as those in DNA damage repair genes for poly (ADP-ribose) polymerase (PARP) inhibition. In addition, several new liquid biopsy fields are emerging, including the characterization of heterogeneity, CTC RNA sequencing, the culture and xenografting of CTCs, and the characterization of extracellular vesicles (EVs) and circulating microRNAs. This review describes the clinical utilization of liquid biopsies in the management of PC patients and emerging liquid biopsy technologies with the potential to advance personalized cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|